Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive dose-ranging trial of canakinumab for acute gout flares
2008-004666-61Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-blind trial of canakinumab in gout (2 arms), sponsored by Novartis. Primary endpoint: Target dose determination based on pain intensity at 72 hours. Started Sep 2008; status: completed.
02
Drugs
canakinumab
03
Conditions
gout
Beyond the preview
Go deeper on 2008-004666-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004666-61.